share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/26 16:06
Moomoo AI 已提取核心訊息
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the U.S. Securities and Exchange Commission on April 26, 2024. The report announces the departure of Dr. Bankole A. Johnson from the company. On April 24, 2024, Adial Pharmaceuticals entered into a Separation Agreement with Dr. Johnson, which includes a one-time separation fee of $54,375. Additionally, the company may engage Dr. Johnson for consulting services at a rate of $850 per hour and he may be eligible for payments under the company's grant incentive plan related to the development of AD04, with potential payments up to $225,000 upon achieving certain milestones by December 31, 2024. The agreement also features a general release of all claims against the company and a mutual non-disparagement clause. The full text of the Separation Agreement is attached to the report as Exhibit 10.1.
Adial Pharmaceuticals, Inc., a Delaware-incorporated company listed on the Nasdaq Capital Market under the trading symbol ADIL, has filed a Form 8-K with the U.S. Securities and Exchange Commission on April 26, 2024. The report announces the departure of Dr. Bankole A. Johnson from the company. On April 24, 2024, Adial Pharmaceuticals entered into a Separation Agreement with Dr. Johnson, which includes a one-time separation fee of $54,375. Additionally, the company may engage Dr. Johnson for consulting services at a rate of $850 per hour and he may be eligible for payments under the company's grant incentive plan related to the development of AD04, with potential payments up to $225,000 upon achieving certain milestones by December 31, 2024. The agreement also features a general release of all claims against the company and a mutual non-disparagement clause. The full text of the Separation Agreement is attached to the report as Exhibit 10.1.
Adial Pharmicals, Inc. 是一家在納斯達克資本市場上市的特拉華州註冊公司，交易代碼爲ADIL，該公司已於2024年4月26日向美國證券交易委員會提交了8-K表格。該報告宣佈班科爾·約翰遜博士離開該公司。2024年4月24日，Adial Pharmicals與約翰遜博士簽訂了分離協議，其中包括54,375美元的一次性離職費。此外，公司可能聘請約翰遜博士以每小時850美元的費率提供諮詢服務，根據公司與AD04開發相關的贈款激勵計劃，他可能有資格獲得付款，在2024年12月31日之前實現某些里程碑後，可能的補助金最高可達22.5萬美元。該協議還規定全面解除對公司的所有索賠，並附有相互不貶損條款。分居協議的全文作爲附錄10.1附在報告中。
Adial Pharmicals, Inc. 是一家在納斯達克資本市場上市的特拉華州註冊公司，交易代碼爲ADIL，該公司已於2024年4月26日向美國證券交易委員會提交了8-K表格。該報告宣佈班科爾·約翰遜博士離開該公司。2024年4月24日，Adial Pharmicals與約翰遜博士簽訂了分離協議，其中包括54,375美元的一次性離職費。此外，公司可能聘請約翰遜博士以每小時850美元的費率提供諮詢服務，根據公司與AD04開發相關的贈款激勵計劃，他可能有資格獲得付款，在2024年12月31日之前實現某些里程碑後，可能的補助金最高可達22.5萬美元。該協議還規定全面解除對公司的所有索賠，並附有相互不貶損條款。分居協議的全文作爲附錄10.1附在報告中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息